RxDoctor Payments Data

Anju Laxman

Family · Conroe, TXNPI 1437641792

Payments from drug & device makers

$1,202in general payments, 2019–2025

Across 50 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$211
  • Lilly USA, LLC$203
  • Bayer$171
  • Amgen$123
  • AstraZeneca$115
  • Merck$112
  • plus $266 from 8 others

What the payments were for

  • Food & beverage$1,16997%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,202 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$18,891
Medicare patients
60
Services billed
394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide36$34,501
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,932
MounjaroTirzepatide15$15,292
Tresiba Flextouch U-200Insulin Degludec11$9,332
Levothyroxine Sodium59$568
Atorvastatin Calcium69$510
Albuterol Sulfate HfaAlbuterol Sulfate19$456
Omega-3 Acid Ethyl Esters18$421
Pantoprazole Sodium27$374
Tamsulosin Hcl19$331
Amlodipine Besylate36$329
Rosuvastatin Calcium33$315
Metoprolol Succinate19$305
Losartan Potassium32$284
Liothyronine Sodium12$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$211$34,50136 claims
GSKTrelegy Ellipta$17$18,93229 claims
Lilly USA, LLCMounjaro$203$15,29215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →